208 related articles for article (PubMed ID: 25111232)
1. Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.
Kramer M; Halleran D; Rahman M; Iqbal M; Anwar MI; Sabet S; Ackad E; Yousef MS
PLoS One; 2014; 9(8):e104425. PubMed ID: 25111232
[TBL] [Abstract][Full Text] [Related]
2. A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity.
Rimmert B; Sabet S; Ackad E; Yousef MS
J Biomol Struct Dyn; 2014; 32(6):950-8. PubMed ID: 23768174
[TBL] [Abstract][Full Text] [Related]
3. The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.
Hamad HA; Thurston J; Teague T; Ackad E; Yousef MS
PLoS One; 2016; 11(12):e0168002. PubMed ID: 27936126
[TBL] [Abstract][Full Text] [Related]
4. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
5. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
6. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.
Soumana DI; Kurt Yilmaz N; Ali A; Prachanronarong KL; Schiffer CA
J Am Chem Soc; 2016 Sep; 138(36):11850-9. PubMed ID: 27512818
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.
Welsch C; Domingues FS; Susser S; Antes I; Hartmann C; Mayr G; Schlicker A; Sarrazin C; Albrecht M; Zeuzem S; Lengauer T
Genome Biol; 2008 Jan; 9(1):R16. PubMed ID: 18215275
[TBL] [Abstract][Full Text] [Related]
8. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
9. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
[TBL] [Abstract][Full Text] [Related]
10. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
11. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
[TBL] [Abstract][Full Text] [Related]
12. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
[No Abstract] [Full Text] [Related]
14. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
15. Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein.
Xue W; Yang Y; Wang X; Liu H; Yao X
PLoS One; 2014; 9(2):e87077. PubMed ID: 24586263
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.
Provazzi PJ; Mukherjee S; Hanson AM; Nogueira ML; Carneiro BM; Frick DN; Rahal P
PLoS One; 2015; 10(12):e0144638. PubMed ID: 26658750
[TBL] [Abstract][Full Text] [Related]
18. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
Fatima K; Tahir M; Qadri I
Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
[TBL] [Abstract][Full Text] [Related]
19. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
20. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N; Lennerstrand J
Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
